3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Brain Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Polycythemia Vera
4
Glioblastoma
4
Meningioma
3
Leukemia, Myeloid, Acute
3
Pharyngeal Neoplasms
2
Paranasal Sinus Neoplasms
2
Neoplasms
2
Laryngeal Neoplasms
2
Head and Neck Neoplasms
2
Gliosarcoma
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Nose Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Glioma
1
Epstein-Barr Virus Infections
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Astrocytoma
1
Adenocarcinoma
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
30
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
20
Papillomavirus Vaccines
9
Radiotherapy, Intensity-Modulated
4
Cisplatin
4
Blood Specimen Collection
4
fludarabine
3
Vaccines, Synthetic
3
Engerix-B
3
Cyclophosphamide
3
halofantrine
2
fludarabine phosphate
2
aldesleukin
2
Watchful Waiting
2
Vaccines
2
Patient Navigation
2
Paclitaxel
2
Light Coagulation
2
Interleukin-2
2
Imiquimod
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Hepatitis A Vaccines
2
Fluorouracil
2
Electrocoagulation
2
Cetuximab
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
utomilumab
1
polyphenon E
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Papillomavirus Infections
×
Hydroxyurea
×
Clear all
NCT02258659
2024-09-24
OPTIMA
University of Chicago
Phase 2
Completed
62 enrolled
13 charts